Abstract
Globally, 296 million people are infected with hepatitis B virus (HBV), and approximately one million people die annually from HBV-related causes, including liver cancer. Although there is a preventative vaccine and antiviral therapies suppressing HBV replication, there is no cure. Intensive efforts are under way to develop curative HBV therapies. Currently, only a few biomarkers are available for monitoring or predicting HBV disease progression and treatment response. As new therapies become available, new biomarkers to monitor viral and host responses are urgently needed. In October 2020, the International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) held a virtual and interactive workshop on HBV biomarkers endorsed by the International HBV Meeting. Various stakeholders from academia, clinical practice and the pharmaceutical industry, with complementary expertise, presented and participated in panel discussions. The clinical utility of both classic and emerging viral and immunological serum biomarkers with respect to the course of infection, disease progression, and response to current and emerging treatments was appraised. The latest advances were discussed, and knowledge gaps in understanding and interpretation of HBV biomarkers were identified. This Roadmap summarizes the strengths, weaknesses, opportunities and challenges of HBV biomarkers.
Key points
-
As new therapies for hepatitis B virus (HBV) infection become available, new biomarkers to monitor viral and host responses are urgently needed.
-
This Roadmap summarizes current knowledge on existing and emerging serum biomarkers in the context of chronic HBV infection.
-
This Roadmap discusses the strengths, weaknesses, opportunities and challenges of serum HBV biomarkers.
-
This Roadmap provides suggestions of the way forward to advance the biomarkers required to fast-track an HBV cure for all, irrespective of resources, HBV genotype or disease stage.
Introduction
Hepatitis B virus (HBV) infection can cause chronic hepatitis B (CHB), which can result in severe liver disease, including cirrhosis and liver cancer. A major challenge to recovery, even in treated individuals, is the persistence of two forms of the viral genome in hepatocytes: the replication-competent, episomal, covalently closed circular DNA (cccDNA), and the linear subgenomic HBV sequences integrated into the human genome, which do not sustain viral replication but can express some HBV antigens1. High viral loads and antigens can lead to T and/or B cell exhaustion and downregulation of innate immune sensors and pathways2,3,4,5,6,7. Current antiviral therapies, which include nucleos(t)ide analogues (NUCs) and pegylated interferon-α (peg-IFNα), decrease viral loads and lead to remission of the disease. However, although NUCs are well tolerated, they require lifelong treatment and do not target cccDNA directly8. Conversely, peg-IFNα, the only finite treatment for CHB, is less well tolerated but might affect cccDNA directly and indirectly9. Treatment results in hepatitis B surface antigen (HBsAg) loss (also known as functional cure) in a minority of cases10,11. Consequently, new effective, finite and well-tolerated cure therapies are being sought to induce functional cure, fully controlling HBV replication and gene expression and/or ultimately eliminating cccDNA and integrated HBV DNA (also known as sterilizing cure)10,11.
CHB is a major global health challenge, and there is an urgent need to develop curative therapies for patients with CHB worldwide12. In 2020, mortality from human immunodeficiency virus (HIV) infection, malaria and tuberculosis continued to decline, but death attributable to viral hepatitis is still increasing13, with rates predicted to double by 2040, even though effective cures for hepatitis C virus are already available. The World Health Organization (WHO) set a goal for the elimination of viral hepatitis with a 90% reduction of new HBV cases by 2030; it is unlikely to be achieved without a substantial increase in the rate of HBV diagnosis. It is estimated that less than 10% of individuals with HBV infection have been identified, and only 10% of the eligible patients receive treatment globally12. To achieve the goal set by WHO, a panel of serum biomarkers will likely be required for surveillance to predict treatment response and outcome as an armamentarium of new therapies is developed. Although a limited number of biomarkers is available that permits monitoring of HBV DNA replication and treatment response to current treatment regimens, biomarkers accurately predicting functional cure are lacking. With more than 40 new therapeutic approaches in preclinical or clinical trials14,15 targeting HBV replication or stimulating HBV-specific host immune responses, identifying suitable biomarkers will become increasingly important.
In October 2020, the International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) held a virtual and interactive workshop on HBV biomarkers, at which stakeholders from academia, clinical practice and the pharmaceutical industry, with complementary expertise, presented and participated in panel discussions. The clinical utility of both classic and emerging, viral and immunological serum biomarkers with respect to the course of infection, disease progression, and response to current and emerging treatments was appraised. The latest advances were discussed and knowledge gaps in our understanding and interpretation of HBV biomarkers were identified.
This Roadmap summarizes current knowledge for existing and emerging HBV virological and immune-related biomarkers and suggests a road forward to advance the biomarkers required to fast-track an HBV cure for all, irrespective of resources, HBV genotype or disease stage.
HBV biomarkers
HBV cccDNA, the key molecule in the HBV life cycle, is first generated from incoming virions and exists as a stable minichromosome in non-dividing hepatocytes1,16. cccDNA is the template for transcription of all HBV RNAs17, including the pre-genomic RNA (pgRNA) replication intermediate that is reverse transcribed into new HBV genomes. Thus, cccDNA is responsible for the production of virions and subviral particles. A detailed description of the viral life cycle has been previously presented18. Integrated HBV sequences can encode HBsAg and seem to be a major source of HBsAg in patients who are negative for hepatitis B e antigen (HBeAg)19. In addition, integrated sequences can produce truncated HBV RNAs and hepatitis B virus x (HBx) protein.
Serum biomarkers currently used in clinical practice to discriminate CHB and disease stages20 include quantitative HBsAg, HBeAg, HBV DNA (Fig. 1) and alanine aminotransferase (ALT) serum levels. However, these biomarkers are not universally available, particularly in resource-limited settings (discussed later), and the classification and use of these classic markers do not completely reflect CHB complexity or HBV intrahepatic activity16. Intrahepatic measurement of cccDNA and viral RNAs might improve disease classification but entail using liver biopsy samples, which are invasive, not routine CHB care and unavailable in resource-limited settings. Furthermore, only a small section of the liver is sampled by liver biopsies, and HBV is unevenly distributed in the liver21,22. Although specific quantitative polymerase chain reactions (PCRs) for cccDNA have been developed23,24, the coexistence of HBV replicative DNA intermediates in infected cells16, including relaxed circular and integrated HBV DNA molecules, interferes with accurate cccDNA quantification. In this respect, a global collaborative project initiated by ICE-HBV aims to optimize and harmonize cccDNA detection and quantification protocols in liver tissue and cell culture.
The curves in the upper part of the diagram show the relative concentration of the markers in a typical infection. The lines above the curves show the mean lengths of the detection periods of hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg) as estimated from the numbers of HBV nucleic acid testing (NAT) yields, with and without detectable HBsAg. The lengths of the pre-HBsAg and post-HBsAg window periods (WPs) and pre-NAT and post-NAT WPs as described by Weusten et al.176. In a later stage of occult HBV infection, when titres of antibodies against hepatitis B surface antigen (anti-HBs) have declined to below 10–100 mIU/mL, occult persisting HBV DNA in the liver can reappear in plasma. If infection occurs perinatally or in very early childhood, there is no full recovery because of immune system immaturity, and this can lead to chronic infection in 90% of cases. The duration of HBsAg positivity is thus prolonged. The lower panel of the figure depicts the stages of natural infection according to current European Association for the Study of the Liver (EASL) guidelines (hepatitis B e antigen (HBeAg)-positive or HBeAg-negative disease and/or infection)177. Anti-HBc, hepatitis B c antibody; Anti-HBe, hepatitis B e antibody; HBeAg, hepatitis B e antigen. Adapted with permission from ref.178, Wiley.
Accordingly, there is a pressing need for alternative biomarkers that not only accurately reflect the intrahepatic cccDNA pool and transcriptional activity25,26 but also better characterize the different CHB disease stages and risk of complications, detect HBV integration, improve the determination of hepatocellular carcinoma (HCC) risk, and monitor immune status and response to therapy. For example, one study showed that HBV functional cure in 10 of 14 patients with genotype A HBV infection was associated with anti-HBsAg immune complex peaks that overlapped with ALT flares in serum levels27. This suggests the utility of hepatitis B surface antibody (anti-HBs, also known as HBsAb) immune complexes as a biomarker of functional cure and warrants further investigation in larger studies encompassing additional HBV genotypes.
Ideal biomarkers should be predictive (visible early and indicative of clinical outcome), highly specific and sensitive, HBV (sub)genotype agnostic, correlative with disease activity and severity, reflective of durable viral control, reproducible, non-invasive and accessible, rapid, simple, and inexpensive28. Biomarkers should also be accessible in resource-limited settings.
Various serum HBV markers have been proposed as surrogates for intrahepatic viral activity. These markers include the complete virion (HBV DNA, hepatitis B core antigen (HBcAg), HBsAg), subviral particles (with HBsAg), empty virus particles (with HBsAg and HBcAg but without HBV DNA or RNA), viral particles containing HBV RNA, and HBV core-related antigen (HBcrAg) consisting of the non-particulate HBeAg and the related precore protein that, like HBeAg, is also derived from the precore/core open reading frame29. We have appraised the clinical utility of both classic (HBV DNA, HBeAg and/or hepatitis B e antibody (anti-HBe), HBsAg, anti-HBs and hepatitis B core antibody (anti-HBc)) and emerging (HBV RNA, HBcrAg and HBsAg isoforms) biomarkers of HBV infection with respect to the course of infection, disease progression, and response to current and emerging treatments.
Classic biomarkers: needs and limitations
A summary of classic biomarkers is presented in Supplementary Table 1. More sensitive DNA assays might be beneficial in identifying residual and fluctuating HBV levels30,31, predicting the risk of reactivation or severe outcomes following NUC treatment withdrawal32, assessing the effect of direct antiviral agents on DNA suppression, and accurately detecting occult HBV infection (OBI)33. In light of WHO recommendations that, in settings where antenatal HBV DNA testing is not available, HBeAg testing can be used to determine eligibility for tenofovir therapy to reduce the likelihood of mother-to-child HBV transmission34, there is a need for point-of-care (POC) HBeAg assays, particularly in resource-limited settings. A limitation of all HBsAg assays is that they do not differentiate between HBsAg derived from cccDNA and integrated HBV DNA because the protein derived from either source is identical35. More research is required to determine the usefulness of quantitative anti-HBs, anti-HBe and anti-HBc assays to better characterize the risk of HCC and reactivation of HBV infection following treatment discontinuation or immunosuppression. These markers are proving useful in detecting OBI (discussed later).
Point-of-care testing: an unmet need
WHO has developed a simplified HBV treatment cascade based on the biomarkers of HBsAg, ALT, presence of cirrhosis and HBV DNA levels36. Treatment eligibility requires appropriate screening and assessment for active disease. These tools include rapid diagnostic tests and ELISA for HBsAg, HBV DNA nucleic acid testing (NAT), ALT (liver panel), and fibrosis measurements such as transient elastography or aspartate aminotransferase-to-platelet ratio index (APRI) score. In addition, regular HCC surveillance with abdominal ultrasonography alongside, or not, serum analysis of α-fetoprotein (AFP) serum levels is essential.
Unfortunately, many of these tests are not readily available as required POC tests, particularly in resource-limited settings37. Their availability will be necessary to meet the ASSURED criteria38 (Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free, and Deliverable to those that need them).
Rapid HBsAg screening tests, such as Determine HBsAg 2 (Alere Medical, Chiba-ken, Japan) and VIKIA HBsAg (bioMérieux SA, Marcy-l’Étoile, France), are available for POC screening. POC HBV DNA NAT platforms have been validated or are in development. In addition, fibrosis measurement by transient elastography (FibroScan) can be adopted for POC with a portable FibroScan; however, the availability of transient elastography is sparse in resource-limited settings39.
Rapid diagnostic tests for HBsAg for multiple HBV genotypes and subtypes40, with results available in 30 min, have been developed41. Notably, the sensitivity of HBsAg enzyme-linked immunosorbent assay (ELISA) and rapid diagnostic tests varies for different HBV genotypes41. Genetic variability in the S gene region of HBV can also affect diagnostic efficacy and specificity42,43. HBsAg ELISA tests that include multiple monoclonal antibodies in the capture phase, together with a polyclonal conjugate phase, are more accurate. HBsAg rapid diagnostic tests are generally less sensitive than lab-based ELISA tests. In our opinion, rapid diagnostic tests, such as Determine and VIKIA, are adequate for HBV screening but are not ideal for monitoring treatment response.
Dried blood spot (DBS) tests have numerous advantages compared to obtaining a standard blood sample; namely, the capillary finger-stick does not require trained health workers, high blood volumes, basic lab facilities, electric power, or a cold chain for transport and storage44. In 2017, WHO conditionally recommended the use of DBS specimens as an option for HBV DNA NAT in settings where there were no facilities or expertise to take venous blood specimens and for persons with poor venous access36. Meta-analysis of 12 studies from Europe (France, Denmark, Germany and Spain), Africa (Ethiopia, Congo, Egypt and Zambia), India and Mexico comparing the sensitivity and specificity of DBS versus serum samples for HBV DNA showed that DBS sensitivity ranged from 93% to 100% and specificity from 70% to 100%44. The limit of detection of the HBV DNA assays for serum samples ranged from 10 IU/ml to 100 IU/ml. HBV DNA detection limits from DBS specimens ranged from approximately 900 IU/ml to 4,000 IU/ml (ref.44). Potential issues identified were the various lengths of storage before testing, ambient temperature variations, and the absence of manufacturer validation for the use of their assays with DBS samples or standardization of technical guidance. Many manufacturers and investigators have validated NAT using DBS by standardized procedures.
DBS have also been used in the HBcrAg assay, showing that HBcrAg correlated strongly with HBV DNA levels for genotypes A–E in individuals with high viral load, suggesting that DBS might be useful in resource-limited settings with limited access to NAT45. However, the assay used to measure HBcrAg, LUMIPULSE chemiluminescent enzyme immunoassay (Fujirebio, Tokyo, Japan), is currently not widely available.
Several POC or near POC NAT platforms have been developed for other blood-borne viruses, including the Xpert HCV Viral Load FS assay (Cepheid, USA), Genefrive (Manchester, UK) and the Alere (Abbott, USA). The GeneExpert platform (Cepheid, USA) is widely available across resource-limited settings where it is used routinely for tuberculosis diagnostics and HIV viral load monitoring. It is also being used to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, a GenExpert viral load assay has also been developed for HBV, which should be readily available in many resource-limited settings where GeneExpert machines have been placed to monitor other pathogens46,47. Fibrosis measurement by transient elastography can be adopted for POC with a portable FibroScan. FibroScan is the preferred method for cirrhosis and fibrosis assessment, with improved performance compared to APRI/FIB4 (ref.48). Improving the availability of the portable FibroScan in resource-limited settings should be prioritized. It is important to note that hepatic inflammation and non-fasting states can falsely increase fibrosis scores with FibroScan, so the results need to be interpreted with care.
To establish a POC model for HBV management in resource-limited settings, standardized diagnostic assays with rapid diagnostic tests or DBS using currently available HBV DNA and HBsAg biomarkers are urgently required. Together with practical and effective guidelines for disease monitoring and therapy, this will assist in reaching the WHO goals of HBV elimination, particularly in resource-limited settings, where the HBV burden is highest.
Novel or emerging biomarkers
HBV RNA
HBV cccDNA is the template for five viral transcripts: precore/core RNA, pgRNA, preS1 RNA, preS2/S RNA and X RNA17,49,50. pgRNA and precore RNA are over-length molecules of approximately 3.5-kb in size, and hence can only be transcribed from cccDNA51,52,53,54,55. Additional molecules transcribed from cccDNA include 5′ truncated RNAs with 3′ poly(A) tails56,57 and HBx RNA55,58. Subgenomic RNAs encoding HBx or HBsAg can also be transcribed from integrated HBV DNA, which could be 5′ truncated with poly(A) tails. At least 15 splice variants of pgRNA54,55,56 and two splice variants of preS2/S mRNA17, which arise from co-transcriptional processing, have been isolated from the supernatant of transfected cell lines or primary human hepatocytes54 and patient sera54,59,60,61. The majority of splice variants identified to date encode the 5′ region of pgRNA and their contribution to pgRNA levels detected in RNA PCR assays requires investigation.
Viral RNA does not circulate freely52 but is found in virus-like particles in serum (or supernatant of cultured cells)51,56,62. HBV RNA can also be found in capsid-antibody complexes62 and naked capsids51,62. The secreted HBV RNA-containing viral particles have a similar buoyant density to HBV DNA-containing particles. However, they are produced at lower levels and, when reverse transcription is blocked, levels increase relative to HBV DNA-containing particles53. The quasispecies of serum and intrahepatic HBV RNA are similar and homologous to cccDNA56.
Various strategies for measuring HBV RNA are shown in Table 1. Few comparisons of the different assays have been performed so far and no widely accepted (international) RNA standard is currently available63.
Clinical relevance of HBV RNA
The ratios of the different forms of HBV RNA and their importance during the different clinical phases or treatment responses are unknown. However, we consider that HBV RNA shows promise as a biomarker of treatment responses that are not predicted by serum HBV DNA levels using current NUC therapy in some settings. HBV RNA kinetics are predictors of response to treatment in patients who are HBeAg positive64. Even though HBV DNA levels decrease following NUC treatment, HBV pgRNA levels can remain relatively high, decreasing at a later stage63. This decoupling of pgRNA to HBV DNA levels can enable pgRNA to be used as a surrogate marker for cccDNA activity or cccDNA copies in the cell under NUC therapy63.
In the absence of therapeutic intervention, the level of HBV RNA in serum generally correlates closely with HBV DNA, albeit 1.5–2 logs lower65,66. The prognostic usefulness of HBV RNA in following the natural history of infection is uncertain and it has become clear, through the preparation of this Roadmap, that there is a paucity of data on its ability to predict liver-related complications, including cirrhosis or HCC. Serum HBV RNA and intrahepatic HBV RNA (primarily full-length encapsidated pgRNA51,67) levels were lower in patients with inactive HBV than in patients with CHB who were either HBeAg positive or HBeAg negative65,68. In patients with CHB, HBV RNA levels varied according to HBeAg status (being higher in patients who were HBeAg positive), with liver inflammation, HBV genotype, and basal core promoter and/or precore mutants24,53,66,69. In the HBeAg-positive phase, serum HBV RNA levels showed a better correlation to serum HBV DNA levels than to either HBsAg or HBeAg66. This correlation seemed to be genotype dependent, with HBV RNA showing a strong correlation with HBV DNA levels for genotype A and with HBsAg levels for genotypes B and C; these associations were weakest for genotype D66. The correlation of HBV RNA with HBV DNA held during the HBeAg-negative phase, with genotype-specific correlations of HBV RNA levels only determined for genotypes A and D66. The weak correlation between HBV RNA levels and HBsAg in the HBeAg-negative phase is most likely due to the large proportion of HBsAg being expressed from integrated HBV DNA.
The decline of both full-length and subgenomic HBV RNA at 3 and 6 months after the initiation of NUC treatment was the strongest predictor of HBeAg seroconversion compared to other markers, including serum levels of HBV DNA, HBsAg, HBeAg, HBcrAg and ALT as well as sex, age and HBV genotype64,70. Together with HBcrAg, serum HBV RNA levels are also a prognostic biomarker for predicting ALT flares and the likelihood of HBV reactivation following cessation of NUC therapy in the absence of detectable HBV DNA32,71. In patients who were HBeAg positive, HBV RNA correlated strongly with HBcrAg levels but this was not observed in patients who were HBeAg negative32,71. Increased HBV RNA levels can also be a marker for viral relapse after NUC discontinuation72,73.
As serum pgRNA is derived exclusively from HBV cccDNA, its measurement can reflect cccDNA activity1. It might also serve as a surrogate marker to assess the target engagement of drugs affecting serum RNA levels by affecting RNA transcription, pgRNA stability and pgRNA packaging (that is, pegylated interferons, small interfering RNAs, antisense oligonucleotides, core protein assembly modulators (also known as capsid assembly modulators (CAMs)). Indeed, the CAM NVR 3–778 plus peg-IFNα but not the NUC entecavir lowered the concentration levels of HBV RNA in serum without causing substantial changes in cccDNA loads71,74,75. Peg-IFNα treatment reduced HBV RNA levels in the liver and serum of humanized mice, with good correlations between serum and intrahepatic pgRNA levels but not with cccDNA levels, as such pgRNA reduction mostly reflected the suppression of cccDNA activity76. In patients who are HBeAg positive, low HBV RNA levels can also help predict response, HBeAg loss and sustained virological control off-treatment after peg-IFNα and combined peg-IFNα–NUC therapy52,77. Although the relevance and correlation between viral RNA serum levels and liver damage still need clarification, serum HBV RNA could help define treatment end points51,78.
HBV RNA can be an addition to HBV DNA as a biomarker in some settings, particularly in predicting which patients will benefit most from treatment cessation. However, because the contributions of serum HBV RNA derived from cccDNA, integrated HBV DNA, or splice variants were unresolved and different quantitative methods were used79, the clinical and biological importance of serum HBV RNA levels should be interpreted with caution. There are also currently no HBV RNA standards available to validate and compare assays in different laboratories. The current Abbott HBV RNA assay has utilized WHO-approved DNA standards32,63 and, until appropriate HBV RNA standards are developed and calibrated, WHO DNA standards will continue to be used where applicable. HBV RNA was undetectable by currently available assays in more than 50% of patients who were HBeAg negative and on long-term NUC therapy and could even be undetectable in patients with low HBV DNA levels (as in HBeAg-negative infection)32 who had not received treatment, suggesting the sensitivity of detection needs improvement, especially with regards to possible cross-reaction with HBV DNA. However, HBV RNA could be detected in patients who were HBV DNA negative and was shown to be an accurate predictor for patients who might relapse following NUC treatment cessation32, demonstrating the promise of this biomarker in clinical settings.
Hepatitis B core-related antigen
HBcrAg, a composite antigen found in the blood of patients with HBV infection, has emerged as a potential marker to monitor intrahepatic cccDNA and its transcriptional activity, thereby defining new meaningful treatment end points80,81,82. HBcrAg components and their biogenesis are illustrated in Fig. 2. Each HBcrAg component can have distinct functions and applications in reflecting intrahepatic viral activities29,83, varying between genotypes and individual patients29.
Hepatitis B core antigen (HBcAg), translated from pre-genomic RNA (pgRNA), forms the icosahedral capsid inside complete and empty virions179. The direct translation product from the precore mRNA is the precore precursor protein (p25), from which hepatitis B virus e antigen (HBeAg) and precore (PreC; also known as p22cr) are both derived. Removal of the N-terminal signal peptide of p25, by the signal peptidase during p25 translocation into the endoplasmic reticulum lumen, leads to the production of p22 (ref.180), which is further processed at its C-terminal domain (CTD) before being secreted as the dimeric HBeAg (p17)181,182. cccDNA, covalently closed circular DNA; HBc, hepatitis B c; HBcrAg, hepatitis B virus core-related antigen; NTD, N-terminal domain; ORF, open reading frame. Adapted with permission from ref.29, American Society for Microbiology.
Clinical relevance of HBcrAg
HBcrAg can distinguish the different clinical phases of CHB83,84, although this ability is limited by the presence of basal core promoter and/or precore mutants that influence HBeAg levels. Serum HBcrAg levels were higher in the HBeAg-positive phase than in the HBeAg-negative phase82,85,86, and correlation with intrahepatic cccDNA levels and transcriptional activity was stronger during HBeAg-positive CHB82. HBcrAg also showed potential for distinguishing between HBeAg-negative inactive and active disease82,85,87,88,89,90,91. Using principal component analysis, researchers could discriminate between patients who were HBeAg positive or HBeAg negative. When HBcrAg was considered, a third group of patients was identified characterized by higher cccDNA, transcriptional activity, high fibrosis and necro-inflammatory activity that could not be discriminated by serum HBV DNA and HBeAg alone32,82,92. Multiple studies show that HBcrAg correlated well with pgRNA in HBeAg-negative CHB. An improved assay for HBcrAg assay with 10-fold increased sensitivity compared to previous assays has been developed93.
HBV DNA and pgRNA levels in the liver were higher in patients who were HBcrAg positive than in those who were HBcrAg negative, suggesting active HBV replication in HBcrAg-positive livers94. HBcrAg was a non-inferior biomarker to HBV DNA in predicting cirrhosis in patients who were HBeAg negative95, with elevated HBcrAg levels in patients with CHB who were treatment naive and HBeAg negative, correlating with increased risk of progression to cirrhosis96. Thus, although an elevated HBV DNA level is still the main indicator for initiation of NUC treatment, HBcrAg might also have a role in identifying patients of high risk with an intermediate HBV viral load who could benefit from early NUC treatment to prevent progression to cirrhosis96. HBcrAg levels can also predict the risk of HCC82,94, which is important as NUC therapy does not eliminate this risk97. In a large study of 2,666 patients with CHB who were infected with genotypes B or C, HBcrAg was an independent risk factor for HCC (209 patients were positive for HCC)98. Whether this observation applies to patients with different HBV genotypes requires investigation. Despite sustained viral suppression, persistently high levels of on-treatment HBcrAg and detectable levels after antiviral therapy termination might predict long-term HCC risk in patients with CHB treated with NUC94,97,99. Detection of residual HBcrAg, in combination with secreted HBV RNA but not HBV DNA, also predicted severe relapse following NUC treatment withdrawal in three of four patients32 and might be a useful biomarker to contraindicate NUC re-treatment and predict relapse100 following treatment cessation.
HBcrAg is also associated with response to current antiviral therapy for HBeAg-positive CHB101 and, together with secreted HBV RNA, should be considered when evaluating new antiviral therapies aiming at a functional cure by direct or indirect targeting of the intrahepatic cccDNA activity102. Although used in Japan, further studies are needed to inform whether HBcrAg can be used in clinical practice more broadly.
HBcrAg assay
The current commercial HBcrAg assay, the chemiluminescent enzyme immunoassay (CLEIA; Lumipulse G HBcrAg, Fujirebio), is for research use only. It detects a combination of HBcAg, HBeAg (both free and in the HBeAg–HBe antibody complex) and precore proteins in the blood following sodium dodecyl sulfate and heat treatment103,104,105 and has been validated for DBS45. The relative contribution of each component of HBcrAg in this assay has not been elucidated and affects the accuracy and utility of HBcrAg as a biomarker for cccDNA. Both viral and host factors can affect the expression of the different components of HBcrAg. Mutations that affect HBeAg (and precore) expression can influence HBcrAg levels, and this reduction obviously cannot be correlated to a reduction of cccDNA activity or copy number. This is also true for increased clearance of HBeAg (and precore) from the serum via a peripheral mechanism such as antibody-mediated clearance29,106.
HBsAg isoforms
The HBsAg components, large and medium surface proteins, differ during the various phases of CHB107 and have different dynamics under treatment107,108. Except for genotype G, which has impaired HBsAg release, no difference in glycosylation, subcellular distribution, release of HBsAg or formation of subviral particles was evident between genotypes when compared in vitro109. However, there were differences in the proportions of HBsAg isoforms both intracellularly and extracellularly between different genotypes, with different post-translational modification patterns for large surface proteins109. Large and medium surface proteins were shown in patients to decrease earlier than small surface proteins prior to HBsAg loss, suggesting that these proteins might represent promising novel biomarker candidates to predict functional cure108. However, more basic research is required to understand the biology of HBsAg isoforms and their clinical relevance, particularly as surrogate markers for HBsAg expression from cccDNA versus integrated HBV DNA and to ascertain if they provide additional diagnostic benefits for the staging of CHB or in monitoring response to current treatment modalities; they might prove to be valuable in monitoring future therapeutic approaches.
HBV biomarkers during treatment
Receiver operating characteristic curves showed that absolute HBV RNA levels were consistently superior to the change from baseline for predicting peg-IFNα response in patients77. No single biomarker seemed superior when comparing HBV RNA, HBV DNA, HBeAg and HBsAg. However, HBV RNA and HBsAg were more accurate at predicting non-responders than HBeAg and HBV DNA77. Furthermore, patients with CHB who were HBeAg negative and treated with peg-IFNα showed rapid HBV RNA decline that correlated with treatment response and long-term HBsAg loss110. This finding likely reflects the ability of peg-IFNα to act as an immune modulator and to lower HBV transcript levels. Similarly, HBcrAg was associated with treatment response for NUC, with and without peg-IFNα, in patients with CHB who were HBeAg positive and in those with CHB who were HBeAg negative101,111. However, HΒcrAg was not superior to HBsAg in predicting therapy response.
The different mechanisms of action of HBV drugs might affect the performance of HBV serum biomarkers, and this needs to be considered, particularly as new therapies targeting different aspects of the HBV life cycle are developed. For example, the reduction in RNA levels was consistently higher in patients treated with CAMs in combination with NUCs than in those treated with NUCs alone112. The reduction of serum HBV RNA during treatment with CAMs is consistent with their mechanism, which blocks pgRNA packaging into capsids as required for their secretion into blood113. In this case, serum RNA will no longer correlate with cccDNA levels or transcriptional activity but can serve to monitor target engagement.
Immunological serum biomarkers
In CHB, HBV persists with dynamic variations in hepatocellular injury with inflammation versus disease and/or virus control and the participation of multiple immune effectors and regulatory pathways2,3,4,5,6,7. Given the lack of safe and convenient access to the liver compartment, examining the serum immune markers is needed to gain mechanistic, clinical and prognostic insights.
As HBV is non-cytopathic, HBV-associated liver disease is largely immune mediated, with the host immune response being induced upon viral recognition (Fig. 3). HBV persistence is associated with global and virus-specific adaptive immune dysregulation or tolerance. In persistent HBV infection without a robust adaptive immune response, multiple inflammatory mechanisms can be activated to mediate hepatocellular injury114. The immune exhaustion, tolerance and pathogenic mechanisms with associated markers and cell subsets, summarized in Box 1, also provide potential avenues for therapeutic immune restoration115.
Control of hepatitis B virus (HBV) infection requires both cellular (CD4+ and CD8+ T cells) and humoral (antibody production by B cells) arms. Using both cytolytic and cytokine-mediated non-cytolytic mechanisms and major histocompatibility (MHC) class I and class II antigen recognition, CD8+ T cells have a primary effector role to kill and cure HBV-infected hepatocytes7,114. CD4+ T cells have a key regulatory role144,183. Neutralizing antibodies to hepatitis B surface antigen (anti-HBsAg) bind circulating virus, thereby reducing viral spread and providing protective immunity184. A key role for B cells in protective immunity to HBV has also been suggested by the high rate of HBV reactivation in patients undergoing B cell depletion with anti-CD20 (ref.185). IFNγ, interferon-γ.
A challenge and opportunity is the measurement of biomarkers in serum that can reflect immunological activity in the liver. In theory, this could be achieved using cytokines, chemokines, and immune regulatory and metabolic factors that can be followed in relation to the clinical course of CHB and response to antiviral therapy (Box 2). Currently, none of these markers seems to be superior to other clinical and virological measures, and further investigations are required to evaluate the potential clinical role of these markers. However, they might collectively provide insights to host responses during novel HBV therapies with potential mechanistic and prognostic implications. In this regard, as a first option, serum biomarkers (for example, cytokines, chemokines, metabolic markers, soluble PD1, soluble CD14) might be more readily examined in clinical studies as only a small amount of blood is needed to measure hundreds of markers simultaneously in highly multiplexed assays116. A second option is the examination of cellular immune phenotype and function in peripheral blood. This approach can vary in complexity yet can be feasible at scale once optimized, and can range from a simple cytokine stimulation assay to assess HBV-specific T cells similar to what has been done for coronavirus disease 2019 (COVID-19)117,118,119 or the diagnostic test for tuberculosis that uses an IFNγ release assay120, to a more complex phenotypic and functional analysis. Considering global and virus-specific immune dysfunction in CHB, a therapeutic goal is to achieve sustained virus control with immune restoration by suppressing viral antigen expression and the viral life cycle. Accordingly, there is a strong rationale to examine how the immune phenotype and function are affected by novel therapies, including immune-modulatory therapies such as Toll-like receptors agonists, therapeutic vaccines, checkpoint inhibitors and those targeting the viral life cycle with potential immune effect121. As a third option, despite growing challenges, direct sampling of the intrahepatic compartment (for example, through liver biopsy) is needed to visualize viral and immune markers simultaneously122,123, and such analyses can currently be done more comprehensively by using various emerging highly multiplexed and computational approaches124,125,126 to better understand the spatial landscape of HBV and host responses in the liver.
Biomarkers of occult HBV infection
OBI is defined as the presence of cccDNA in the liver and/or HBV DNA in the blood of people who tested negative for HBsAg by currently available assays33,127. Statements on the biology and clinical effect of OBI suggested that the ideal diagnosis method for OBI is the detection of replication-competent HBV DNA in the liver33. The recommended methods included nested-PCR techniques to amplify at least three different viral genomic regions, real-time PCR assays or droplet digital PCR (ddPCR) assays. In each case, the assay must include primer sets enabling the detection of replication-competent HBV DNA33.
The diagnosis of OBI depends on the sensitivity of assays used to detect HBV DNA in liver tissue and/or blood samples and HBsAg in serum samples. Sensitivity for HBV DNA detection is improving with new technologies such as ddPCR assays. In a study of 100 transplant liver donors who were anti-HBc positive, OBI was diagnosed using four parallel nested PCRs to detect HBV surface, core, polymerase and X sequences128. Next, ddPCR was used to quantify cccDNA, which was detected in 52% (52 of 100) of the individuals who were OBI positive, with a median of 13 copies per 105 cells (95% CI 5–25)128. More sensitive HBsAg assays have also been developed. Commonly used assays detect HBsAg at 0.05 IU/ml; however, the newly developed assays can detect HBsAg with a sensitivity of 0.005 IU/ml (ref.129). These more sensitive assays can improve the detection rate of low-level HBsAg, HBsAg variants, and HBsAg with anti-HBs130,131 and can provide improved detection of OBI132.
In addition to HBsAg assays, inadequately sensitive HBV DNA assays can lead to false-negative HBV DNA results and a missed OBI diagnosis30. Commercially available real-time PCR-based assays for serum HBV DNA detection are sufficiently sensitive to detect many (but not all) OBI cases. ddPCR assays might increase the rate of OBI detection and need to be evaluated systematically in the OBI setting. In addition, consideration should be given to the need to diagnose OBI by re-screening samples by ddPCR, which is only accessible via research facilities but not routinely available in diagnostic laboratories31,133.
Lessons can be learned from HBV reactivation studies in patients with chronic hepatitis C treated with direct-acting antiviral agents. Nested-PCR testing of longitudinally collected serum samples from 40 patients revealed that serum HBV DNA was intermittently detected in 25% (10 of 40) at baseline and 52.5% (21 of 40) at 3 months after termination of direct-acting antiviral treatment. Moreover, HBsAg and HBcrAg biomarkers were negative at baseline and remained persistently negative (without any fluctuation) in all the serially collected serum samples134. Thus, as HBV DNA is usually present in low concentrations and can only be intermittently detected in people with OBI, testing blood samples collected at more than one timepoint and testing DNA extracts from at least 1 ml of serum or plasma is recommended for OBI diagnosis33,127. Indeed, it should be considered that OBI is characterized by periods of transient HBV viraemia alternating with periods in which the viral DNA is undetectable in blood135,136,137,138. Moreover, evidence demonstrated an association between the reappearance of circulating HBV DNA and phases of ALT serum level increases, suggesting a role in the transient reactivation of HBV replication in liver cell injury136,137. Furthermore, Candotti et al. described nine cases of undetected HBV transfusion-transmission from OBI-positive blood donation despite the use of highly sensitive HBsAg and HBV DNA screening assays30. Importantly, the availability of archive samples from both donors and recipients and large-volume (2–24 ml) follow-up donor samples enabled the researchers to detect HBV transfusion-transmitted infection associated with extremely low HBV DNA loads. These results led the researchers to conclude that, until more sensitive assays become available, long-term archiving of large-volume pretransfusion plasma samples from both donors and recipients is essential to identify transfusion-transmission of undetected OBI to limit delays in the therapeutic management of patients with HBV infection30.
As molecular tests are not always available, there is a strong consensus that detection of anti-HBc in the blood can be used as a surrogate biomarker for OBI in blood and/or organ donors and in people initiating immunosuppressive therapies33,139. Although serum levels of anti-HBc correlate with cccDNA positivity128, the absence of anti-HBc does not rule out OBI33. High baseline levels of anti-HBc (and low or absent anti-HBs) were shown to predict HBV reactivation in 36 of 192 patients with lymphoma and resolved HBV infection receiving B cell-depleting chemotherapies (hazard ratio of 17.29 for HBV reactivation (95% CI 3.92–76.30; P <0.001))140,141. Anti-HBc quantification and analysis of circulating HBV-specific T cells in patients who are HBsAg negative might be interesting biomarkers but require further confirmation in the setting of OBI. Currently, HBV DNA is the only reliable diagnostic marker of OBI and a standardized diagnostic procedure for OBI remains an important unmet clinical need.
Biomarkers of liver cancer
Chronic HBV infection causes liver cancer, the sixth most common cancer and the third leading cause of cancer-related death worldwide. HCC is more common in men (2–4 times higher incidence than in women) and the prognosis is poor in all regions of the world, with incidence and mortality rates being roughly equivalent. The median survival of patients with early HCC is >5 years but is <1 year when detected at an advanced stage. Due to a lack of appropriate biomarkers, most HCC cases are detected at late stages and not when the tumour is still localized and treatment options are more effective142.
Currently, HCC surveillance relies on a limited armoury of serum biomarkers and/or imaging of the affected liver. Cancer biomarkers are detected in the blood, urine or other body fluids and can indicate the presence of cancer or predict the risk of cancer development143. Ideally, biomarkers should enable early detection of cancer by screening healthy or high-risk populations, confirming the diagnosis or identifying a specific type of cancer, predicting prognosis, monitoring treatment response, and detecting early recurrence142.
The identification of biomarkers for the early detection of cancer requires the following steps131:
-
Phase 1: Preclinical exploratory studies: to identify promising biomarker candidates.
-
Phase 2: Clinical assay and validation: to detect the disease versus controls (for example, distinguish HCC from non-HCC).
-
Phase 3: Retrospective longitudinal repository studies: to detect preclinical disease by retrospective analysis.
-
Phase 4: Prospective screening studies: to determine the detection rate of the assay (sensitivity and specificity).
-
Phase 5: Cancer control studies: to assess the effect of screening on reducing the disease burden in the target population.
Over the past several decades, AFP has been the most extensively studied and most commonly used HCC biomarker. It has been utilized for the assessment risk of HCC in patients with cirrhosis, as a screening tool for the early detection of HCC, and as a diagnostic and prognostic tool for HCC144. In addition to AFP, a number of novel biomarkers for HCC diagnosis and monitoring are in different phases of development. Serum biomarkers currently in phase 2 (clinical assay and validation) include osteopontin, midikine, dikkopf 1, glypican 3, α1 fucosidase, Golgi protein 73 and squamous cell carcinoma antigen145,146,147. Serum biomarkers at more advanced stages of development include AFP (phase 5), Lens culinaris agglutinin fraction of AFP (AFP-L3) (phase 2/3) and des-γ-carboxy prothrombin (DCP) (phase 2/3)142. Genetic and cellular biomarkers (so-called liquid biopsy) under investigation include circulating tumour cells, circulating tumour DNA, microRNA and long non-coding RNA148.
AFP is the best characterized and most widely used serum biomarker for HCC surveillance. However, its effectiveness is limited as not all HCCs secrete AFP149. In addition, AFP serum levels can be elevated in patients with chronic hepatitis or cirrhosis. However, with the advent of highly effective NUCs for the treatment of CHB, elevated on-treatment AFP levels were shown in a large retrospective-prospective study to be a specific marker for HCC because falsely elevated AFP levels in 1,531 patients receiving entecavir were minimized compared to 424 patients that received no treatment, suggesting that, in this group of patients, a lower AFP cut off value could be used150. Elevated on-treatment AFP is a specific tumour marker for HCC in patients with CHB receiving entecavir150. There is little debate that AFP should not be used alone in HCC surveillance, but it has been debated whether AFP should be included in HCC surveillance due to its suboptimal sensitivity (39–65%) and specificity (76–97%)151. However, most studies show a benefit of combining AFP with ultrasonography152. Various factors can influence the performance of AFP as an HCC biomarker, including patient demographics, aetiology of underlying liver disease, severity of liver disease (cirrhosis, chronic hepatitis, serum ALT values), antiviral therapy, and tumour stage and biology153. In turn, according to the size of the tumour, the sensitivity of ultrasonography imaging for detecting HCC at an early stage is highly variable, ranging from 21% to 89% across studies included in a meta-analysis published in 2018 (ref.152). It is largely operator dependent, based on the skill of the sonographer and influenced by patient characteristics, including obesity, liver nodularity and presence of ascites154,155,156. A meta-analysis of 32 studies comprising 13,367 patients collected worldwide showed that ultrasonography alone detected early-stage HCC with a sensitivity of 45% compared to 63% when ultrasonography was combined with AFP (P = 0.002)152. The improved sensitivity was associated with a decrease in specificity (84% versus 92%). However, the addition of AFP to ultrasonography significantly increased the sensitivity of early HCC detection, suggesting this might be the preferred surveillance strategy for patients with cirrhosis152. Other factors to consider are the value of single timepoint versus longitudinal analysis and tailoring cut-offs according to liver disease aetiology, severity and antiviral therapy. The diagnostic value of AFP for detecting HCC was also improved when used in combination with the level of serum protein induced by vitamin K absence or antagonist II (PIVKAII) in patients of European descent157 and Asian158 (South Korea) patients with cirrhosis.
Longitudinal determinations also improve AFP performance as an HCC biomarker159. A phase III biomarker study evaluating AFP, AFP-L3, DCP and their combinations for the early detection of HCC in prospectively collected longitudinal samples from 689 patients with cirrhosis or CHB160 showed that a combination of AFP and AFP-L3 at diagnosis differentiated early-stage HCC from cirrhosis better than each biomarker individually. Investigating the sensitivity and specificity of ultrasonography alone or in combination with biomarkers showed that adding AFP to ultrasonography increased the sensitivity to 88.6%, and adding AFP plus AFP-L3 to ultrasonography increased the sensitivity to 94.3%160.
In summary, although the addition of AFP to ultrasonography imaging markedly improved the early detection of HCC, results are still suboptimal and new biomarkers to predict early-onset HCC are required. Longitudinal determination of AFP increases the sensitivity and specificity for HCC surveillance but optimal cut-offs for AFP and other biomarkers of HCC surveillance in patients with suppressed HBV and minimal hepatic inflammation are unclear. Given the high degree of heterogeneity of HCC, the combination of AFP with other biomarkers and clinical parameters improves the sensitivity and specificity of surveillance for early HCC detection.
The road forward
To map a way forward, the clinical utility of both classic and emerging viral and immunological biomarkers of HBV infection, with respect to the course of infection, disease progression, and response to current and emerging treatments, was appraised in two-panel discussions. The panels discussed the latest advances, knowledge gaps, and key challenges and opportunities for improvement were identified by addressing three key questions: do we have the appropriate biomarkers to measure HBV cccDNA, and are the emerging biomarkers relevant for measuring the mechanism of action of new drugs? What are the key biomarkers that require further research to have the strongest clinical effect? Finally, how urgent is the need for predictive immunological biomarkers for inflammation or antiviral response? The strengths and weakness of current biomarkers for addressing each of these questions are presented in Table 2, with a Roadmap outlining the actions required to address unmet clinical needs presented in Table 3.
For patients with CHB undergoing, or ceasing current NUC therapy, no single biomarker is currently clearly superior in predicting treatment response or relapse across all stages of CHB. There is global consensus that achieving an HBV cure will require combination therapies, targeting different steps of the HBV replication cycle, and stimulating host immune responses to neutralize HBV infection and/or safely eradicate HBV-infected cells26. In turn, approaches that affect viral and immunological targets will require a combination of viral and immunological biomarkers to monitor progress towards the new treatment end points.
For the immediate future, HBeAg, HBsAg and HBV DNA will remain the most important viral serum biomarkers used in natural history and treatment end points because they are best validated to reflect outcomes. It is evident that biomarkers have different importance in various disease stages (HBeAg positive versus HBeAg negative), HBV genotypes and for different treatment modalities. On the other hand, HBV RNA and HBcrAg are expected to correlate with treatment response to current and new therapies but might not outperform HBsAg in predicting treatment outcome when each is taken in isolation. HBV RNA, HBcrAg and/or HBcAg tests need to be validated and standardized, and their sensitivity optimized. New biomarkers can help to dissect the mechanism of action of new drugs. Another possible benefit of these emerging biomarkers is their clinical usefulness in combination with conventional markers such as the demonstrated superiority of combining pgRNA and HBsAg levels at the time of stopping NUC for the prediction of off-treatment viral relapse71.
It is also important that biomarkers are validated for all major HBV genotypes, which exhibit marked differences in HBV natural history, disease progression and treatment response to peg-IFNα therapy161. Until new immune-mediated therapies are developed, peg-IFNα is likely to have a place in combination treatment regimens, yet it is only effective in patients with HBV infection of genotypes A and B and least effective for genotypes C and D. Although HBV sequencing and genotyping are not currently routinely undertaken prior to treatment initiation, this might need to be considered if peg-IFNα is included in treatment combinations. Although not routinely available in all settings, next-generation sequencing of complete HBV genomes prior to the initiation of antiviral therapy also shows promise as a biomarker of treatment response on NUCs, with the identification of basal core promoter mutations even at a low frequency associated with reduced likelihood of functional cure162 and ALT flare163 on therapy. As new curative therapies for HBV are developed, the effect of HBV variants on treatment response warrants further investigation where access to next-generation sequencing technology is available.
Although a number of biomarkers have been described that can monitor the course of HBV infection, it is vital, when interpreting their kinetics and variations, to determine whether they are informing on target engagement of the therapeutic agent and/or are a reflection of intrahepatic replication and immune control. The emerging biomarkers will have an important role as exploratory markers for end points and mode-of-action studies. No one biomarker yet fits all novel antiviral modalities, and an integrative approach might be necessary because the serological marker used is dependent on the mode of action of the antiviral drugs. More translational studies are required, and the relevance of these assays in the various phases of CHB natural history and in individuals of different ethnicities, age groups, sex and HBV genotypes is yet to be determined.
Currently, there are no serum or liver immunological biomarkers that are superior to clinical and virological markers in following the natural history of CHB and in monitoring therapy and HBV-specific immune responses. Markers that reflect the liver compartment will become increasingly important as access to liver tissue and standard liver biopsy become more difficult, with fine-needle aspiration (also known as fine-needle biopsy) showing promise. Monitoring intrahepatic activity will become increasingly important as therapies targeting HBV cccDNA are developed. However, in the interim, consideration should also be given to identifying the most appropriate biomarkers for treatment response using finite therapies that might reduce HBV DNA to below the limit of quantification but where HBsAg remains detectable, currently defined as a ‘partial functional cure’164. ‘Partial functional cure’ might represent an important interim step as we progress on the path to increased rates of functional cure with new finite therapies. It is likely that pgRNA, HBcrAg and its HBcAg component as emerging biomarkers as well as additional yet-unidentified markers will have an important role; therefore, an HBcAg-specific biomarker would be a valuable additional tool to help de-convolute the multiple components of the current HBcrAg assay. Biomarkers of OBI are also required as are markers that will predict the likelihood of progression to HCC, enabling earlier interventions and more accurate risk assessment. Finally, all these resources need to be made available to all persons living with CHB in an equitable and fair manner, and particularly in resource-limited settings, where much of the burden of HBV worldwide lies, with a pressing need for POC biomarkers. In partnership with the HBV-affected community, academia, clinicians, the pharmaceutical and biotech industries, and organizations such as the HBV Forum and the Hepatitis B Foundation, ICE-HBV will work with all stakeholders to ensure this indeed occurs.
References
Tong, S. & Revill, P. Overview of hepatitis B viral replication and genetic variability. J. Hepatol. 64, S4–S16 (2016).
Faure-Dupuy, S., Lucifora, J. & Durantel, D. Interplay between the hepatitis B virus and innate immunity: from an understanding to the development of therapeutic concepts. Viruses https://doi.org/10.3390/v9050095 (2017).
Bertoletti, A. & Ferrari, C. Adaptive immunity in HBV infection. J. Hepatol. 64, S71–S83 (2016).
Maini, M. K. & Gehring, A. J. The role of innate immunity in the immunopathology and treatment of HBV infection. J. Hepatol. 64, S60–S70 (2016).
Kuipery, A., Gehring, A. J. & Isogawa, M. Mechanisms of HBV immune evasion. Antivir. Res. 179, 104816 (2020).
Rehermann, B. & Thimme, R. Insights from antiviral therapy into immune responses to hepatitis B and C virus infection. Gastroenterology 156, 369–383 (2019).
Bengsch, B. & Chang, K. M. Evolution in our understanding of hepatitis B virus virology and immunology. Clin. Liver Dis. 20, 629–644 (2016).
Grossi, G., Vigano, M., Loglio, A. & Lampertico, P. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). Liver Int. 37 (Suppl. 1), 45–51 (2017).
Lucifora, J. et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343, 1221–1228 (2014).
Lok, A. S., Zoulim, F., Dusheiko, G. & Ghany, M. G. Hepatitis B cure: from discovery to regulatory approval. J. Hepatol. 67, 847–861 (2017).
Revill, P. A. et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol. Hepatol. 4, 545–558 (2019).
WHO. Interim Guidance for Country Validation of Viral Hepatitis Elimination https://www.who.int/publications/i/item/9789240028395 (2021).
Thomas, D. L. Global elimination of chronic hepatitis. N. Engl. J. Med. 380, 2041–2050 (2019).
Revill, P. A., Penicaud, C., Brechot, C. & Zoulim, F. Meeting the challenge of eliminating chronic hepatitis B infection. Genes https://doi.org/10.3390/genes10040260 (2019).
Hepatitis B Foundation. Hepatitis B Foundation Drugwatch, https://www.hepb.org/treatment-and-management/drug-watch/ (2022).
Testoni, B., Levrero, M. & Zoulim, F. Challenges to a cure for HBV infection. Semin. Liver Dis. 37, 231–242 (2017).
Sommer, G. & Heise, T. Posttranscriptional control of HBV gene expression. Front. Biosci. 13, 5533–5547 (2008).
Yuen, M. F. et al. Hepatitis B virus infection. Nat. Rev. Dis. Prim. 4, 18035 (2018).
Wooddell, C. I. et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aan0241 (2017).
Gish, R. G. et al. Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities. Antivir. Res. 121, 47–58 (2015).
Liu, D. et al. Clinical relevance of the in situ assay for HBV DNA: a cross-sectional study in patients with chronic hepatitis B. J. Clin. Pathol. 73, 813–818 (2020).
Zhang, X. et al. In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection. J. Clin. Investig. 126, 1079–1092 (2016).
Bowden, S., Jackson, K., Littlejohn, M. & Locarnini, S. Quantification of HBV covalently closed circular DNA from liver tissue by real-time PCR. Methods Mol. Med. 95, 41–50 (2004).
Werle-Lapostolle, B. et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126, 1750–1758 (2004).
Coffin, C. S., Zhou, K. & Terrault, N. A. New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection. Gastroenterology 156, 355–368 e353 (2019).
Revill, P. A. et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol. Hepatol. 4, 545–558 (2019).
Xu, H. et al. Role of anti-HBs in functional cure of HBeAg+chronic hepatitis B patients infected with HBV genotype A. J. Hepatol. 76, 34–45 (2022).
Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89–95 (2001).
Hong, X. et al. Characterization of hepatitis B precore/core-related antigens. J. Virol. https://doi.org/10.1128/JVI.01695-20 (2021).
Candotti, D., Assennato, S. M., Laperche, S., Allain, J. P. & Levicnik-Stezinar, S. Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose. Gut 68, 313–321 (2019).
Piermatteo, L. et al. Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment. Methods 201, 74–81 (2022).
Carey, I. et al. Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen-negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy. Hepatology 72, 42–57 (2020).
Raimondo, G. et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J. Hepatol. 71, 397–408 (2019).
WHO. Prevention of Mother-to-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy https://apps.who.int/iris/bitstream/handle/10665/333391/9789240002708-eng.pdf?sequence=1&isAllowed=y (2020).
Cornberg, M. et al. The role of quantitative hepatitis B surface antigen revisited. J. Hepatol. 66, 398–411 (2017).
WHO. WHO Guidelines on Hepatitis B and C Testing https://apps.who.int/iris/bitstream/handle/10665/254621/9789241549981-eng.pdf?sequence=1 (2017).
Kramvis, A. Challenges for hepatitis B virus cure in resource-limited settings in sub-Saharan Africa. Curr. Opin. Hiv. AIDS 15, 185–192 (2020).
Kosack, C. S., Page, A. L. & Klatser, P. R. A guide to aid the selection of diagnostic tests. Bull. World Health Organ. 95, 639–645 (2017).
Sonderup, M. W. & Spearman, C. W. Global disparities in hepatitis B elimination — a focus on Africa. Viruses https://doi.org/10.3390/v14010082 (2022).
Scheiblauer, H. et al. Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes. Vox Sang. 98, 403–414 (2010).
Chevaliez, S. & Pawlotsky, J. M. New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings. J. Hepatol. 69, 916–926 (2018).
Alavian, S. M., Carman, W. F. & Jazayeri, S. M. HBsAg variants: diagnostic-escape and diagnostic dilemma. J. Clin. Virol. 57, 201–208 (2013).
Thibault, V., Servant-Delmas, A., Ly, T. D., Roque-Afonso, A. M. & Laperche, S. Performance of HBsAg quantification assays for detection of Hepatitis B virus genotypes and diagnostic escape-variants in clinical samples. J. Clin. Virol. 89, 14–21 (2017).
Lange, B. et al. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis. BMC Infect. Dis. 17, 693 (2017).
Shimakawa, Y. et al. Analytical validation of hepatitis B core-related antigen (HBcrAg) using dried blood spots (DBS). J. Viral Hepat. 28, 837–843 (2021).
Jackson, K., Tekoaua, R., Li, X. & Locarnini, S. Real-world application of the Xpert(R) HBV viral load assay on serum and dried blood spots. J. Med. Virol. 93, 3707–3713 (2021).
Abravanel, F. et al. Performance of the Xpert HBV Viral Load assay versus the Aptima Quant assay for quantifying hepatitis B virus DNA. Diagn. Microbiol. Infect. Dis. 96, 114946 (2020).
Zhu, X. et al. Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy/AST platelet ratio index and FIB-4 in patients with chronic HBV infection. Dig. Dis. Sci. 56, 2742–2749 (2011).
Gerlich, W. H., Glebe, D., Kramvis, A. & Magnius, L. O. Peculiarities in the designations of hepatitis B virus genes, their products, and their antigenic specificities: a potential source of misunderstandings. Virus Genes 56, 109–119 (2020).
Seeger, C. & Mason, W. S. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64, 51–68 (2000).
Wang, J. et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J. Hepatol. 65, 700–710 (2016).
Jansen, L. et al. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon Alfa-2a and nucleos(t)ide analogues. J. Infect. Dis. 213, 224–232 (2016).
Prakash, K. et al. High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles. Virol. J. 15, 86 (2018).
Lam, A. M. et al. Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants. Antimicrob. Agents Chemother. https://doi.org/10.1128/AAC.00680-17 (2017).
Stadelmayer, B. et al. Full-length 5’RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum. J. Hepatol. 73, 40–51 (2020).
Wang, J. et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. J. Hepatol. 68, 16–24 (2018).
Hacker, H. J., Zhang, W., Tokus, M., Bock, T. & Schroder, C. H. Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy. Ann. N. Y. Acad. Sci. 1022, 271–281 (2004).
Niu, C. et al. The Smc5/6 complex restricts HBV when localized to ND10 without inducing an innate immune response and is counteracted by the HBV X protein shortly after infection. PLoS One 12, e0169648 (2017).
Wang, J. et al. HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient. J. Hepatol. 68, 847–849 (2018).
Gunther, S., Sommer, G., Iwanska, A. & Will, H. Heterogeneity and common features of defective hepatitis B virus genomes derived from spliced pregenomic RNA. Virology 238, 363–371 (1997).
Lim, C. S. et al. Quantitative analysis of the splice variants expressed by the major hepatitis B virus genotypes. Microb. Genom. https://doi.org/10.1099/mgen.0.000492 (2021).
Bai, L. et al. Extracellular hepatitis B virus RNAs are heterogeneous in length and circulate as capsid-antibody complexes in addition to virions in chronic hepatitis B patients. J. Virol. https://doi.org/10.1128/JVI.00798-18 (2018).
Butler, E. K. et al. Hepatitis B virus serum DNA and RNA levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection. Hepatology 68, 2106–2117 (2018).
van Bommel, F. et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 61, 66–76 (2015).
Mak, L. Y. et al. HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy. Hepatology 73, 2167–2179 (2021).
van Campenhout, M. J. H. et al. Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. Hepatology 68, 839–847 (2018).
Anderson, M. et al. Circulating pregenomic HBV RNA is primarily full-length in chronic hepatitis B patients undergoing nucleos(t)ide analogue therapy. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa1015 (2020).
Wang, J. et al. Natural history of serum HBV-RNA in chronic HBV infection. J. Viral Hepat. 25, 1038–1047 (2018).
Volz, T. et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 133, 843–852 (2007).
Cathcart, A. L. et al. Evaluation of serum HBV RNA and HBcrAg in chronic hepatitis B patients achieving different serological outcomes on tenofovir disoproxil fumarate (TDF). J. Hepatol. 66, S476 (2017).
Seto, W. K. et al. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. Gut 70, 775–783 (2021).
van Bömmel, F. et al. HBV RNA can still be quantified in serum in HBeAg negative patients after suppression of HBV DNA by nuleos(t)ide analogues for up to 10 years. Hepatology 68 (Suppl.), 273A (2018).
Fan, R. et al. Association between negative results from tests for hBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy. Clin. Gastroenterol. Hepatol. 18, 719–727.e7 (2020).
Klumpp, K. et al. Efficacy of NVR 3-778, alone and in combination with pegylated interferon, vs entecavir in uPA/SCID mice with humanized livers and HBV infection. Gastroenterology 154, 652–662.e8 (2018).
Yuen, M. F. et al. Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection. Gastroenterology 156, 1392–1403.e7 (2019).
Giersch, K., Allweiss, L., Volz, T., Dandri, M. & Lutgehetmann, M. Serum HBV pgRNA as a clinical marker for cccDNA activity. J. Hepatol. 66, 460–462 (2017).
van Bommel, F. et al. Serum HBV RNA as a predictor of peginterferon Alfa-2a response in patients with HBeAg-positive chronic hepatitis B. J. Infect. Dis. 218, 1066–1074 (2018).
Hu, J. & Liu, K. Complete and incomplete hepatitis B virus particles: formation, function, and application. Viruses https://doi.org/10.3390/v9030056 (2017).
Liu, Y. Y. & Liang, X. S. Progression and status of antiviral monitoring in patients with chronic hepatitis B: from HBsAg to HBV RNA. World J. Hepatol. 10, 603–611 (2018).
Suzuki, F., Miyakoshi, H., Kobayashi, M. & Kumada, H. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J. Med. Virol. 81, 27–33 (2009).
Hige, S. et al. Sensitive assay for quantification of hepatitis B virus mutants by use of a minor groove binder probe and peptide nucleic acids. J. Clin. Microbiol. 48, 4487–4494 (2010).
Testoni, B. et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J. Hepatol. 70, 615–625 (2019).
Mak, L. Y. & Yuen, M. F. Letter: serum HBcrAg is a useful marker for disease monitoring, predicting treatment response and disease outcome of chronic hepatitis B virus infection-authors’ reply. Aliment. Pharmacol. Ther. 47, 1720–1721 (2018).
Mak, L. Y. et al. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment. Pharmacol. Therapeut. 47, 43–54 (2018).
Maasoumy, B. et al. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. Clin. Microbiol. Infect. 21, 606.e1-10 (2015).
Wong, G. L., Wong, V. W. & Chan, H. L. Virus and host testing to manage chronic hepatitis B. Clin. Infect. Dis. 62 (Suppl. 4), S298–305 (2016).
Chen, E. Q. et al. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B. Sci. Rep. 7, 173 (2017).
Suzuki, Y. et al. Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma. Hepatol. Res. 49, 51–63 (2019).
Seto, W. K. et al. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Clin. Microbiol. Infect. 20, 1173–1180 (2014).
Riveiro-Barciela, M. et al. Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus genotype. Clin. Microbiol. Infect. 23, 860–867 (2017).
Brunetto, M. R. et al. Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis. Aliment. Pharmacol. Therapeut. 53, 733–744 (2021).
Chuaypen, N. et al. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy. Clin. Microbiol. Infect. 24, 306.e7–306.e13 (2018).
Inoue, T. et al. Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J. Hepatol. https://doi.org/10.1016/j.jhep.2021.02.017 (2021).
Honda, M. et al. Hepatitis B virus (HBV) core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma. J. Infect. Dis. 213, 1096–1106 (2016).
Tseng, T. C. et al. Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. Aliment. Pharmacol. Therapeut. 53, 908–918 (2021).
Tada, T. et al. Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers. J. Gastroenterol. Hepatol. 33, 918–925 (2018).
Hosaka, T. et al. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. Aliment. Pharmacol. Therapeut. 49, 457–471 (2019).
Tseng, T. C. et al. High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology 157, 1518–1529.e3 (2019).
Hosaka, T. Letter: impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues-further clarifications needed. Authors’ reply. Aliment. Pharmacol. Therapeut. 50, 233 (2019).
Wong, D. K. et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int. 37, 995–1001 (2017).
van Campenhout, M. J. et al. Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients. Clin. Microbiol. Infect. 22, 571.e5-9 (2016).
Matsuzaki, T. et al. Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation. J. Gastroenterol. Hepatol. 28, 1217–1222 (2013).
Kimura, T. et al. Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain. J. Biol. Chem. 280, 21713–21719 (2005).
Kimura, T. et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J. Clin. Microbiol. 40, 439–445 (2002).
Fanning, G. C., Zoulim, F., Hou, J. & Bertoletti, A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat. Rev. Drug Discov. 18, 827–844 (2019).
Hong, X. et al. Characterization and application of precore/core-related antigens in animal models of hepatitis B virus infection. Hepatology https://doi.org/10.1002/hep.31720 (2021).
Pfefferkorn, M. et al. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Gut 67, 2045–2053 (2018).
Pfefferkorn, M. et al. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. J. Hepatol. 74, 283–292 (2021).
Hassemer, M. et al. Comparative characterization of hepatitis B virus surface antigen derived from different hepatitis B virus genotypes. Virology 502, 1–12 (2017).
Farag, M. S. et al. Hepatitis B virus RNA as early predictor for response to PEGylated interferon Alfa in HBeAg negative chronic hepatitis B. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa013 (2020).
van Campenhout, M. J. H. et al. Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B. J. Viral Hepat. 26, 1156–1163 (2019).
Zhang, M. Efficacy and safety of GLS4/ritonavir combined with entecavir in HBeAg-positive patients with chronic hepatitis B: interim results from phase 2b, multi-center study. J. Hepatol. 73, s878 (2020).
Taverniti, V. et al. Capsid assembly modulators as antiviral agents against HBV: molecular mechanisms and clinical perspectives. J. Clin. Med. https://doi.org/10.3390/jcm11051349 (2022).
Ghany, M. G. et al. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. Lancet Gastroenterol. Hepatol. 5, 406–417 (2020).
Maini, M. K. & Burton, A. R. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nat. Rev. Gastroenterol. Hepatol. 16, 662–675 (2019).
Tighe, P. J., Ryder, R. R., Todd, I. & Fairclough, L. C. ELISA in the multiplex era: potentials and pitfalls. Proteom. Clin. Appl. 9, 406–422 (2015).
Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489–1501.e15 (2020).
Le Bert, N. et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J. Exp. Med. https://doi.org/10.1084/jem.20202617 (2021).
Weiskopf, D. et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci. Immunol. https://doi.org/10.1126/sciimmunol.abd2071 (2020).
Mazurek, G. H. & Villarino, M. E.; CDC. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm. Rep. 52, 15–18 (2003).
Cornberg, M., Lok, A. S., Terrault, N. A. & Zoulim, F.; 2019 EASL-AASLD HBV Ttretment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(double dagger). J. Hepatol. 72, 539–557 (2020).
Gill, U. S. et al. Fine needle aspirates comprehensively sample intrahepatic immunity. Gut 68, 1493–1503 (2019).
Gill, U. S., Pallett, L. J., Kennedy, P. T. F. & Maini, M. K. Liver sampling: a vital window into HBV pathogenesis on the path to functional cure. Gut 67, 767–775 (2018).
Hartmann, F. J. & Bendall, S. C. Immune monitoring using mass cytometry and related high-dimensional imaging approaches. Nat. Rev. Rheumatol. 16, 87–99 (2020).
Traum, D. et al. Highly multiplexed 2-dimensional imaging mass cytometry analysis of HBV-infected liver. JCI Insight https://doi.org/10.1172/jci.insight.146883 (2021).
Rendeiro, A. F. et al. The spatial landscape of lung pathology during COVID-19 progression. Nature 593, 564–569 (2021).
Raimondo, G. et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol. 49, 652–657 (2008).
Caviglia, G. P. et al. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: a new tool to detect occult infection. J. Hepatol. 69, 301–307 (2018).
Deguchi, M. et al. Evaluation of the highly sensitive chemiluminescent enzyme immunoassay “Lumipulse HBsAg-HQ” for hepatitis B virus screening. J. Clin. Lab. Anal. 32, e22334 (2018).
Ozeki, I. et al. Analysis of hepatitis B surface antigen (HBsAg) using high-sensitivity HBsAg assays in hepatitis B virus carriers in whom HBsAg seroclearance was confirmed by conventional assays. Hepatol. Res. 48, E263–E274 (2018).
Pepe, M. S. et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054–1061 (2001).
Kuhns, M. C. et al. Improved detection of early acute, late acute, and occult Hepatitis B infections by an increased sensitivity HBsAg assay. J. Clin. Virol. 118, 41–45 (2019).
Liu, Y., Cathcart, A. L., Delaney, W. E. T. & Kitrinos, K. M. Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatment. J. Virol. Methods 249, 189–193 (2017).
Musolino, C. et al. Behaviour of occult HBV infection in HCV-infected patients under treatment with direct-acting antivirals. Antivir. Ther. 24, 187–192 (2019).
Kazemi-Shirazi, L., Petermann, D. & Muller, C. Hepatitis B virus DNA in sera and liver tissue of HBsAg negative patients with chronic hepatitis C. J. Hepatol. 33, 785–790 (2000).
Kannangai, R. et al. Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J. Clin. Virol. 39, 101–105 (2007).
Chemin, I., Guillaud, O., Queyron, P. C. & Trepo, C. Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J. Hepatol. 51, 824–825 (2009).
Saitta, C. et al. Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy. Dig. Liver Dis. 45, 683–686 (2013).
Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7, 6 (2021).
Yang, H. C. et al. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. J. Hepatol. 69, 286–292 (2018).
Kusumoto, S. et al. Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma. J. Hepatol. 73, 285–293 (2020).
Parikh, N. D. et al. Biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol. Biomark. Prev. 29, 2495–2503 (2020).
Chaiteerakij, R., Addissie, B. D. & Roberts, L. R. Update on biomarkers of hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 13, 237–245 (2015).
Guidotti, L. G. et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 284, 825–829 (1999).
Xu, D., Su, C., Sun, L., Gao, Y. & Li, Y. Performance of serum Glypican 3 in diagnosis of hepatocellular carcinoma: a meta-analysis. Ann. Hepatol. 18, 58–67 (2019).
Ge, T. et al. Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma. Med. Oncol. 32, 59 (2015).
Johnson, P. J. et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol. Biomark. Prev. 23, 144–153 (2014).
von Felden, J., Garcia-Lezana, T., Schulze, K., Losic, B. & Villanueva, A. Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut 69, 2025–2034 (2020).
Wang, T. & Zhang, K. H. New blood biomarkers for the diagnosis of AFP-negative hepatocellular carcinoma. Front. Oncol. 10, 1316 (2020).
Wong, G. L. et al. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology 59, 986–995 (2014).
Marrero, J. A. Screening tests for hepatocellular carcinoma. Clin. Liver Dis. 9, 235–251 (2005).
Tzartzeva, K. et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 154, 1706–1718.e1 (2018).
Gopal, P. et al. Factors that affect accuracy of alpha-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 12, 870–877 (2014).
Simmons, O. et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment. Pharmacol. Therapeut. 45, 169–177 (2017).
Del Poggio, P. et al. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 12, 1927–1933.e2 (2014).
Singal, A. G., Lampertico, P. & Nahon, P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J. Hepatol. 72, 250–261 (2020).
Loglio, A. et al. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy. Liver Int. 40, 1987–1996 (2020).
Park, S. J. et al. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. Medicine 96, e5811 (2017).
Lee, E., Edward, S., Singal, A. G., Lavieri, M. S. & Volk, M. Improving screening for hepatocellular carcinoma by incorporating data on levels of alpha-fetoprotein, over time. Clin. Gastroenterol. Hepatol. 11, 437–440 (2013).
Choi, J. et al. Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology 69, 1983–1994 (2019).
Kramvis, A. Genotypes and genetic variability of hepatitis B virus. Intervirology 57, 141–150 (2014).
Bayliss, J. et al. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Gut 66, 2013–2023 (2017).
Wong, D. et al. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B. Liver Int. 38, 1760–1769 (2018).
Cornberg, M. & Glebe, D. Editorial: which factors influence HBsAg levels in HBV-infected patients? Aliment. Pharmacol. Therapeut. 52, 547–548 (2020).
Rokuhara, A. et al. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. J. Gastroenterol. 41, 785–790 (2006).
Wang, J. et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. J. Hepatol. https://doi.org/10.1016/j.jhep.2017.08.021 (2017).
Wang, J. et al. Reply to: “Serum HBV pgRNA as a clinical marker for cccDNA activity”: consistent loss of serum HBV RNA might predict the “para-functional cure” of chronic hepatitis B. J. Hepatol. 66, 462–463 (2017).
Limothai, U. et al. Reverse transcriptase droplet digital PCR vs reverse transcriptase quantitative real-time PCR for serum HBV RNA quantification. J. Med. Virol. https://doi.org/10.1002/jmv.25792 (2020).
van Bommel, F. et al. Serum HBV RNA as a predictor of peginterferon Alfa-2a (40KD) response in patients with HBeAg-positive chronic hepatitis B. J. Infect. Dis. 218, 1066–1074 (2018).
Tsuge, M. et al. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J. Gastroenterol. 48, 1188–1204 (2013).
Huang, Y. W. et al. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy. Antivir. Ther. 20, 369–375 (2015).
Laras, A., Koskinas, J., Dimou, E., Kostamena, A. & Hadziyannis, S. J. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 44, 694–702 (2006).
Scholtès, C. et al. Performance of a novel automated assay for the detection and quantification of HBV pregeomic RNA/ circulating RNAs in chronic HBV patients. Hepatology 72, 447A (2020).
Loggi, E. et al. Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B. J. Viral Hepat. 26, 568–575 (2019).
Lee, H. W. & Ahn, S. H. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. World J. Gastroenterol. 22, 8314–8321 (2016).
Weusten, J., Vermeulen, M., van Drimmelen, H. & Lelie, N. Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms. Transfusion 51, 203–215 (2011).
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370–398 (2017).
Vermeulen, M. et al. Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk. Transfusion 52, 880–892 (2012).
Ning, X. et al. Secretion of genome-free hepatitis B virus–single strand blocking model for virion morphogenesis of para-retrovirus. PLoS Pathog. 7, e1002255 (2011).
Garcia, P. D., Ou, J. H., Rutter, W. J. & Walter, P. Targeting of the hepatitis B virus precore protein to the endoplasmic reticulum membrane: after signal peptide cleavage translocation can be aborted and the product released into the cytoplasm. J. Cell Biol. 106, 1093–1104 (1988).
Ito, K., Kim, K. H., Lok, A. S. & Tong, S. Characterization of genotype-specific carboxyl-terminal cleavage sites of hepatitis B virus e antigen precursor and identification of furin as the candidate enzyme. J. Virol. 83, 3507–3517 (2009).
Wang, J., Lee, A. S. & Ou, J. H. Proteolytic conversion of hepatitis B virus e antigen precursor to end product occurs in a postendoplasmic reticulum compartment. J. Virol. 65, 5080–5083 (1991).
Thimme, R. et al. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 77, 68–76 (2003).
Rehermann, B. Immune responses in hepatitis B virus infection. Semin. Liver Dis. 23, 21–38 (2003).
Seto, W. K. et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J. Clin. Oncol. 32, 3736–3743 (2014).
Hakim, M. S., Spaan, M., Janssen, H. L. & Boonstra, A. Inhibitory receptor molecules in chronic hepatitis B and C infections: novel targets for immunotherapy? Rev. Med. Virol. 24, 125–138 (2014).
Lopes, A. R. et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J. Clin. Invest. 118, 1835–1845 (2008).
Peppa, D. et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J. Exp. Med. 210, 99–114 (2013).
Xu, D. et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J. Immunol. 177, 739–747 (2006).
Stoop, J. N. et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41, 771–778 (2005).
Fisicaro, P. et al. Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches. Front. Immunol. 11, 849 (2020).
Pallett, L. J. et al. Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nat. Med. 21, 591–600 (2015).
Fisicaro, P. et al. Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat. Med. 23, 327–336 (2017).
Salimzadeh, L. et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J. Clin. Invest. 128, 4573–4587 (2018).
Milich, D. & Liang, T. J. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 38, 1075–1086 (2003).
Dunn, C. et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J. Exp. Med. 204, 667–680 (2007).
Das, A. et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J. Exp. Med. 205, 2111–2124 (2008).
Sandalova, E. et al. Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells. Gastroenterology 143, 78–87.e3 (2012).
Aiolfi, R. & Sitia, G. Chronic hepatitis B: role of anti-platelet therapy in inflammation control. Cell Mol. Immunol. 12, 264–268 (2015).
Tiegs, G. & Lohse, A. W. Immune tolerance: what is unique about the liver. J. Autoimmun. 34, 1–6 (2010).
Wohlleber, D. & Knolle, P. A. The role of liver sinusoidal cells in local hepatic immune surveillance. Clin. Transl. Immunol. 5, e117 (2016).
Chang, K. M. et al. Distinct phenotype and function of circulating Vdelta1+and Vdelta2+gammadeltaT-cells in acute and chronic hepatitis B. PLoS Pathog. 15, e1007715 (2019).
Boeijen, L. L. et al. Mucosal-associated invariant T cells are more activated in chronic hepatitis B, but not depleted in blood: reversal by antiviral therapy. J. Infect. Dis. 216, 969–976 (2017).
Yoshio, S. et al. Indoleamine-2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B. Hepatology 63, 83–94 (2016).
Hou, F. Q. et al. Rapid downregulation of programmed death-1 and interferon-gamma-inducible protein-10 expression is associated with favourable outcome during antiviral treatment of chronic hepatitis B. J. Viral Hepat. 20 (Suppl. 1), 18–26 (2013).
Tan, A. T. et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J. Hepatol. 52, 330–339 (2010).
Wang, Y. et al. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients. Antivir. Res. 103, 51–59 (2014).
Chen, Y. et al. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine 56, 231–238 (2011).
Cheng, H. Y. et al. Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma. PLoS One 9, e95870 (2014).
Zhou, L. et al. Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B. J. Viral Hepat. 26, 795–802 (2019).
Jeng, W.-J. & Yang, H.-I. Discrepant range of sPD-1 in different studies of chronic hepatitis B. A letter in response to soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B. J. Viral Hepat. 26, 930–931 (2019).
Jaroszewicz, J. et al. Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir. Ther. 16, 915–924 (2011).
Sonneveld, M. J., Arends, P., Boonstra, A., Hansen, B. E. & Janssen, H. L. Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. J. Hepatol. 58, 898–903 (2013).
Yoshio, S. et al. Cytokine and chemokine signatures associated with hepatitis B surface antigen loss in hepatitis B patients. JCI Insight https://doi.org/10.1172/jci.insight.122268 (2018).
Johnson Valiente, A. et al. The inflammatory cytokine profile associated with liver damage is broader and stronger in patients with chronic hepatitis B compared to patients with acute hepatitis B. J. Infect. Dis. 225, 470–475 (2022).
Xia, J. et al. Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment. Aliment. Pharmacol. Therapeut. 51, 1180–1187 (2020).
Dou, Y. et al. Elevated serum levels of soluble CD14 in HBeAg-positive chronic HBV patients upon Peginterferon treatment are associated with treatment response. J. Viral Hepat. 26, 1076–1085 (2019).
Sandler, N. G. et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 141, 1220–1230 (2011).
Acknowledgements
The authors thank the Workshop Participants: The ICE-HBV HBV Serum Biomarkers Workshop was held virtually in two sessions on 5th and 12th October 2020 (https://ice-hbv.org/hbv-serum-biomarkers-workshop/). The chairs of the workshop A.K. and P.R. organized the meeting with C.P. K.M.C., M.D., P.F., D.G., J.H., H.L.A.J., D.T.Y.L., T.P., B.T. and F.V.P. presented at the workshop. O.A., M.B.M., T.M.B., H.L.Y.C., G.A.C., W.D., A.M.G., A.G., O.L., M.M., V.M., U.P., J.Y., M.F.Y. and F.B. chaired the workshop sessions and/or participated in the panel discussions. The authors thank T. Candy (VIDRL, RMH, Doherty Institute, Melbourne, Victoria, Australia) for assistance with the preparation of the manuscript.
Author information
Authors and Affiliations
Contributions
P.R., A.K., K.M.C., M.D., P.F., D.G., J.H., H.L.J., D.L., M.C.P., T.P., B.T., F.B., O.M.A., M.B.M., T.B., H.L.Y.C., G.A.C., W.E.D., A.M.A.G., A.J.G., K.J., O.L., M.K.M., V.M., U.P., J.C.Y., M.F.Y. and F.Z. researched data for the article. P.R., A.K., K.M.C., M.D., P.F., D.G., J.H., H.L.J., D.L., M.C.P., T.P., B.T., F.B., O.M.A., M.B.M., T.B., H.L.Y.C., G.A.C., W.E.D., A.M.A.G., A.J.G., K.J., O.L., M.K.M., V.M., U.P., J.C.Y., M.F.Y. and F.Z. contributed substantially to discussion of the content. P.R., A.K., K.M.C., M.D., P.F., D.G., J.H., H.L.J., D.L., M.C.P., T.P., B.T., F.B., O.M.A., M.B.M., T.B., H.L.Y.C., G.A.C., W.E.D., A.M.A.G., A.J.G., O.L., M.K.M., V.M., U.P., J.C.Y., M.F.Y. and F.Z. wrote the article. P.R., A.K., K.M.C., M.D., P.F., D.G., J.H., H.L.J., D.L., M.C.P., T.P., B.T., F.B., O.M.A., M.B.M., T.B., H.L.Y.C., G.A.C., W.E.D., A.M.A.G., A.J.G., K.J., O.L., M.K.M., V.M., U.P., J.C.Y., M.F.Y. and F.Z. reviewed and/or edited the manuscript before submission.
Corresponding authors
Ethics declarations
Competing interests
A.K. is a recipient of a grant from the Cancer Association of South Africa (CANSA). K.M.C. is supported by the Corporal Michael J. Crescenz VA Medical Center Research Program in Philadelphia, Pennsylvania 19104, USA and has served in the Scientific Advisory Committee for Arbutus Biopharma. M.D. is supported by the German Research Foundation (DFG; SFB841), the German Center for Infection Research (DZIF) and the Dandri lab has received collaborative funding from Gilead Sciences and MYR-GmbH. P.F. has nothing to declare and is supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MA, USA. D.G. is supported by the German Research Foundation (DFG; SFB1021), the German Center for Infection Research (DZIF), the Robert Koch Institute, Berlin and the German Federal Ministry of Health. J.H. has been supported by funding from the National Institute of Allergy and Infectious Disease/NIH and Gilead for work relevant here and has consulted for Arbutus, Bristol-Myers-Squibb, Gilead, Janssen, Roche and Sanofi. H.L.A.J. received grants from AbbVie, Gilead Sciences, GlaxoSmithKline, Janssen, Roche, Vir Biotechnology Inc. and is a consultant for Aligos, Antios, Arbutus, Eiger, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Roche, VBI Vaccines, Vir Biotechnology Inc. and Viroclinics. D.T.Y.L. received research grants from GlaxoSmithKline, Janssen and Abbott Laboratories. C.P. is a consultant for Janssen. T.P. has been a speaker for Gilead Science. B.T. has nothing to declare. F.V.B. has received research grants from Gilead Sciences, Roche Diagnostics, Ipsen and Janssen; has been part of speaker’s bureau for Gilead Sciences, Roche, Janssen, Ipsen, Eisai, MSD and GSK; and has received support for conference travels from Gilead, Janssen, Roche, Ibsen, MSD and Bayer. O.A. has nothing to disclose, supported by 5R01DK044533-23. M.B.M. is an employee of Janssen Pharmaceuticals. T.M.B. is on the Board of Hepion Pharma and has received support from Arbutus Biopharma and is a co-founder and equity holder in Glycotest. H.L.Y.C. has served as an adviser of AbbVie, Aligos, Arbutus, Gilead, GSK, Hepion, Janssen, Merck, Roche, Vaccitech, VenatoRx, Vir Biotechnology and Virion Therapeutics, and is a speaker for Gilead, Mylan and Roche. G.C. is an Abbott Employee and shareholder. W.E.D. is an employee of and owns stock in Assembly Bio and owns stock in Gilead Sciences. A.M.G. is an employee of Roche Pharma Research and Early Development and also holds stock units with the company. A.G. receives research funding from Janssen Pharmaceuticals, GSK, and Gilead Sciences and conducts consulting/scientific advising for Janssen Pharmaceuticals, Roche, GSK, Vir Biotech, Finch Therapeutics and SQZ Biotech. O.L. is an employee of Janssen Pharmaceutical NV and owns stock of Johnson and Johnson. K.J. performs contract research for Gilead Sciences and Arrowhead Pharmaceuticals. The M.K.M. lab has received collaborative funding from Gilead Sciences, VIR Biotechnology, Hoffmann-La-Roche and GSK (last 3 years), with no funds taken personally. M.K.M. is supported by Wellcome Investigator Award 21419/Z/18/Z. V.M. and the Forum for Collaborative Research, University of California Berkeley School of Public Health, Washington DC Campus, Washington, DC, USA: the Forum received unrestricted support from multiple companies, but did not receive funding specific to the writing of this manuscript. The companies are: Abbott Diagnostics, Aligos Therapeutics, Inc., Altimmune, Antios, Therapeutics, Assembly Biosciences, Eiger Biopharmaceuticals, ENYO Pharma, Gilead, GSK, Immunocore, Janssen Pharmaceuticals ID&V, Monogram Biosciences Quest Diagnostics, Roche Pharma R&D (pRED), Venatorx Pharmaceuticals, Inc., Vir Biotechnology, Virion Therapeutics, LLC, Viroclinics-DDL Diagnostic Laboratory. U.P. is co-founder and shareholder of SCG Cell Therapy, obtained research support from Abbott, ALIOS, Yhlo and VirBio, and received personal fees from Abbvie, Arbutus, Gilead, GSK, J&J, Roche, Sanofi, Sobi and Vaccitech. J.C.Y. was an employee of Gilead Sciences. M.F.Y. reports being an adviser/consultant for and/or having received grant/research support from AbbVie, Aligos Therapeutics, Antios Therapeutics, Arbutus Biopharma, Arrowhead Pharmaceuticals, Assembly Biosciences, Bristol-Myers Squibb, Dicerna Pharmaceuticals, Finch Therapeutics, Fujirebio Incorporation, GlaxoSmithKline, Gilead Sciences, Immunocore, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals, Silverback Therapeutics, Sysmex Corporation, Vir Biotechnology and Roche. F.Z. reports consulting for Aligos, Antios, Arbutus, Assembly, Enochian, Gilead, GSK, Roche Molecular Systems, and Zhimeng and research funding to INSERM from Assembly, Beam and Viravaxx. P.A.R. has previously received research funding from Gilead Sciences and is on the Scientific Advisory Board of Enochian Biosciences.
Peer review
Peer review information
Nature Reviews Gastroenterology & Hepatology thanks Jia-Horng Kao, Philippa Matthews and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Related links
HBV Forum: https://forumresearch.org/hbv-forum/hbv-foruman-overview
Hepatitis B Foundation: https://www.hepb.org/
ICE-HBV: https://ice-hbv.org/
Workshop on HBV biomarkers: https://ice-hbv.org/hbv-serum-biomarkers-workshop/
Supplementary information
Rights and permissions
About this article
Cite this article
Kramvis, A., Chang, KM., Dandri, M. et al. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol 19, 727–745 (2022). https://doi.org/10.1038/s41575-022-00649-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-022-00649-z
